Targeting Adaptive Stress

We have developed a differentiated pipeline of therapy candidates that address dynamic drivers of treatment resistance, cancer relapse and metastasis. We are actively developing our therapeutic candidates in clinical trials for large indications of unmet need for patients.

Our Pipeline

Phase 1
Phase 2
Phase 3
Adaptive Stress Modulators
Advanced HNSCC, CRC, Bladder Cancer & Other Advanced Solid Tumors
HC-7366 monoTx
HC-7366 monoTx
(HIF-2α inhibitor combo)
HC-7366 + HIF-2α
(SOC agents combo)
HC-7366 + SOC agents

HC-7366, our second adaptive stress product candidate, is a differentiated selective, orally bioavailable modulator of a key stress response protein kinase, GCN2.  HC-7366 is under investigation in a Phase 1a/b trial as monotherapy for treatment of advanced solid tumors including, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), transitional cell carcinoma of the bladder, and other solid tumors.  We have initiated the Phase 1b portion of our solid tumor study in RCC and plan to initiate additional Phase 1b combination studies renal cell carcinoma (RCC) and in acute myeloid leukemia (AML).

Advanced RCC, Gastric Cancer & Other Advanced Solid Tumors
HC-5404 monoTx
Solid Tumors
(VEGFR TKI combo)

HC-5404, our first adaptive stress product candidate, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK.  HC-5404 recently completed investigation in a Phase 1a trial as a monotherapy for the treatment of advanced solid tumors enriched for patients with renal cell carcinoma (RCC) and gastric cancer.  Following the completion of our Phase 1a trial, we are now seeking partners for a Phase 1b trial in combination with VEGFR TKIs in multiple solid tumors.

Innate & Adaptive Immune Modulator
CRC-Based Liver Metastasis IIT
(ICI combo)

Odetiglucan (Imprime PGG) is our systemically administered innate and adaptive immune modulator therapeutic candidate.  Odetiglucan has also demonstrated increased response rates and disease control rates in patients with liver metastasis across varied tumor histologies, with multiple therapeutic classes. Odetiglucan will be evaluated in a Phase 2 investigator initiated clinical trial further exploring this mechanism in combination with an immune checkpoint inhibitor in patients with colorectal cancer liver metastasis.

Targeting critical adaptive stress mitigating pathways

Modulating the immune system’s defense mechanisms